Imagine a smart alarm system for your health that catches a joint disease before it even starts. It uses wearable gadgets and special light-based imaging to spot tiny changes in skin and joints. By mixing this with genetic and lifestyle data, it gives doctors a clear map to treat each patient uniquely.
Early diagnosis of Psoriatic Arthritis is currently untraceable and often delayed, leading to rapid deterioration of patient quality of life and increased healthcare costs due to comorbidities.
A digital health ecosystem including AI-based risk prediction models, motor-tracking digital indicators, and optoacoustic imaging markers.
If you are a health-tech app developer dealing with low patient engagement in chronic care — this project developed a digital health ecosystem that provides tailored insights and preventive interventions for people at risk of PsA.
If you are a wearable sensor manufacturer dealing with a lack of clinical use-cases for motor tracking — this project developed digital phenotyping tools that track motor manifestations of inflammation using smart devices.
If you are a medical imaging company dealing with imprecise early-stage arthritis detection — this project developed optoacoustic imaging-based markers to identify PsA in skin and joints.
Based on available project data, no specific pricing or cost information has been disclosed.
The project involves 6 industry partners and 5 SMEs, suggesting a design intended for industrial application and market integration.
Based on available project data, specific licensing terms are not mentioned, though the project follows a trustworthy AI framework for legal robustness.
The project period runs from 2023-01-01 to 2026-12-31, indicating the final tools will be ready by late 2026.
It is designed as a digital health ecosystem with tools for healthcare professionals to support screening, monitoring, and treatment via quantitative evidence.
The consortium is well-balanced for commercialization, featuring 16 partners across 9 countries. With a 38% industry ratio (6 companies, including 5 SMEs), there is a strong bridge between the 7 universities and 3 research centers and the actual market, ensuring the AI tools are developed with commercial viability in mind.
Contact ARISTOTELIO PANEPISTIMIO THESSALONIKIS
Contact us to explore licensing opportunities for the PsA digital phenotyping tools.
